(Reuters Health) - More than three years after Pennsylvania issued a statewide order expanding access to the life-saving opioid antidote naloxone, the product was still hard to purchase in Philadelphia pharmacies, researchers found.
Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.
(Reuters Health) - More than three-quarters of antibiotic prescriptions written by dentists before dental procedures are unnecessary and might do more harm than good, a new U.S. study found.
June 12 Catalyst Pharmaceuticals Inc,
which has come under fire for the high price tag on its rare
disease drug, on Wednesday sued the U.S. Food and Drug
Administration to challenge the recent approval of a lower-cost
(Reuters Health) - Too little sleep - or too much - can be tied to problems with blood sugar levels, not just in people with diabetes but also in people at high risk for developing the disease, a new study finds.
Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.
(Reuters Health) - Women who suffer cardiac arrest outside of a hospital are less likely to receive help from bystanders and have less chance of survival than men, a recent Dutch study showed.
Medtronic Plc reported quarterly profit ahead of estimates on strong demand for its surgical instruments and forecast better-than-expected 2020 earnings on Thursday, sending shares of the medical device maker up nearly 3%.
(Reuters Health) - When people with moderate or severe injuries are discharged from the hospital, follow-up care, especially at rehabilitation centers, is a crucial part of their recovery - but African Americans are less likely than white patients to seek out or receive these important services, a U.S. study suggests.
Array BioPharma Inc's cocktail of three therapies helped patients with a type of colorectal cancer live longer than those on standard treatment, according to interim results of a late-stage study on Tuesday.